Drug Profile
Research programme: lysosomal storage disease therapeutics - ArmaGen Technologies
Latest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator ArmaGen Technologies
- Developer ArmaGen Technologies; Department of Veterans Affairs; Saint Louis University; University of California at Los Angeles; University of Texas Medical Branch
- Class Immunoglobulin fusion proteins; Monoclonal antibodies
- Mechanism of Action Acetylglucosaminidase replacements; Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metachromatic leukodystrophy; Mucopolysaccharidosis III
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for preclinical development in Metachromatic leukodystrophy in USA (IV, Injection)
- 28 Oct 2022 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-III in USA (IV, Infusion)
- 21 Oct 2020 Preclinical development is ongoing for Metachromatic leukodystrophy and Mucopolysaccharidosis-III in USA (ArmaGen Technologies pipeline, October 2020)